News

10x Genomics price target lowered to $12 from $15 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the ...
Longview News-Journal1mon
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.